<SEC-DOCUMENT>0001070081-17-000067.txt : 20170410
<SEC-HEADER>0001070081-17-000067.hdr.sgml : 20170410
<ACCEPTANCE-DATETIME>20170410160225
ACCESSION NUMBER:		0001070081-17-000067
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170407
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170410
DATE AS OF CHANGE:		20170410

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PTC THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001070081
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043416587
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35969
		FILM NUMBER:		17753422

	BUSINESS ADDRESS:	
		STREET 1:		100 CORPORATE COURT
		CITY:			SOUTH PLAINFIELD
		STATE:			NJ
		ZIP:			07080-2449
		BUSINESS PHONE:		9082227000

	MAIL ADDRESS:	
		STREET 1:		100 CORPORATE COURT
		CITY:			SOUTH PLAINFIELD
		STATE:			NJ
		ZIP:			07080-2449

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PTC THERAPEUTICS INC
		DATE OF NAME CHANGE:	19980909
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k_april72017.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s31E1032509ABA9A7B28C5512F92039BD"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM 8-K</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of Report (Date of earliest event reported):  </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">April 7, 2017</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">PTC THERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact Name of Company as Specified in Charter)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:37%;"></td><td style="width:2%;"></td><td style="width:22%;"></td><td style="width:2%;"></td><td style="width:37%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">001-35969</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">04-3416587</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or Other Jurisdiction <br>of Incorporation)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission <br>File Number)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(IRS Employer <br>Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:42%;"></td><td style="width:2%;"></td><td style="width:56%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">100 Corporate Court</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">South Plainfield, NJ</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">07080</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of Principal Executive Offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Zip Code)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Company&#8217;s telephone number, including area code:  </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(908) 222-7000</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Not applicable</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Former Name or Former Address, if Changed Since Last Report)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">see</font><font style="font-family:inherit;font-size:10pt;">&#32;General Instruction A.2. below):</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:5pt;">&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#32;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:5pt;">&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#32;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:5pt;">&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#32;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:5pt;">&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#32;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:100%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 5.02 &#160;&#160;&#160;&#160;Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 7, 2017, Shane Kovacs, Executive Vice President, Chief Financial Officer and Head of Corporate Development of PTC Therapeutics, Inc. (the &#8220;Company&#8221;), notified the Company of his resignation, which is expected to be effective mid-May 2017.  </font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A copy of the press release issued by the Company on April 10, 2017, related to this matter is attached hereto as Exhibit 99.1.</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 8.01.&#160;&#160;&#160;&#160;Other Events</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 7, 2017, the Company received notice from the U.S. Federal Trade Commission that it had granted early termination, effective immediately, of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (&#8220;HSR Act&#8221;) for the Company&#8217;s pending acquisition of all rights to Emflaza&#8482; (deflazacort) from Marathon Pharmaceuticals, LLC (the &#8220;Transaction&#8221;). </font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The early termination of the waiting period under the HSR Act satisfies one of the conditions to the closing of the Transaction, which remains subject to other customary closing conditions. The Company expects to close the Transaction in the next several weeks.</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01.  Financial Statements and Exhibits. </font></div><div style="line-height:120%;text-align:left;padding-left:78px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)</font><font style="font-family:inherit;font-size:3pt;">&#32;&#160;&#160;&#160;&#160;  </font><font style="font-family:inherit;font-size:10pt;">Exhibits:</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1 Press Release dated April 10, 2017</font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cautionary Statement Concerning Forward Looking Statements</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This Current Report on Form 8-K (this "Report") contains forward-looking statements addressing the Transaction and any other statements about future expectations that are dependent upon future events or developments. All statements, other than those of historical fact, contained in this Report are forward-looking statements, including statements related to the Company&#8217;s expectations with respect to the closing of the Transaction and the effective date of Mr. Kovacs&#8217; departure. Other forward-looking statements may be identified by the words "look forward", "plan," "anticipate," "believe," "estimate," "expect," "intend," "may," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions. The Company&#8217;s actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to satisfaction of the conditions to closing the Transaction in the anticipated timeframe or at all (including the failure to obtain necessary regulatory approvals); the Company&#8217;s ability to realize the anticipated benefits of the Transaction, including the possibility that the expected benefits from the Transaction will not be realized or will not be realized within the expected time period; negative effects of announcements related to the Transaction on the market price of the Company&#8217;s common stock; significant transaction costs, unknown liabilities, and the risk of litigation and/or regulatory actions related to the Transaction as well as other business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of Translarna</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(ataluren) and Emflaza; the sufficiency of the Company&#8217;s cash resources and its ability to obtain adequate financing in the future for its foreseeable and unforeseeable operating expenses and capital expenditures; and the factors discussed in the "Risk Factors" section of the Company&#8217;s most recent Annual Report on Form 10-K as well as any updates to these risk factors filed from time to time in PTC's other filings with the SEC. The forward-looking statements contained herein represent the Company's views only as of the date of this Report and the Company does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this Report except as required by law.</font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;text-align:center;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.84126984126983%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:46%;"></td><td style="width:16%;"></td><td style="width:38%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:24px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PTC THERAPEUTICS, INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:24px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: April 10, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:24px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:24px;"><div style="text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Stuart Peltz</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:24px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stuart Peltz</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:24px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT INDEX</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:20%;"></td><td style="width:7%;"></td><td style="width:73%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:24px;"><div style="text-align:left;padding-left:24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:24px;"><div style="text-align:center;padding-left:24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:24px;"><div style="text-align:center;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:24px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press Release dated April 10, 2017</font></div></td></tr></table></div></div><div style="line-height:100%;padding-top:12px;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:180%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:100%;padding-top:12px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit991_april102017.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s3F0C974C086C7139EB9F5831BF35B1BB"></a></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:138%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit 99.1</font></div><div style="line-height:138%;text-align:left;"><img src="workivalogo.jpg" alt="workivalogo.jpg" style="height:86px;width:152px;"></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">PTC Therapeutics Announces Departure of Chief Financial Officer, Shane Kovacs</font></div><div style="line-height:138%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SOUTH PLAINFIELD, N.J., April 10, 2016 &#8211; </font><font style="font-family:inherit;font-size:11pt;">PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Shane Kovacs, Chief Financial Officer, will be leaving the company in mid-May 2017 to return to the finance sector, joining RBC Capital Markets as Managing Director where he will help lead the firm&#8217;s biotech investment banking efforts. </font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">PTC has initiated a search process to appoint a new CFO.  Shane is expected to remain with PTC through the closing of PTC&#8217;s pending acquisition of all rights to Emflaza&#8482; (deflazacort) from Marathon Pharmaceuticals, LLC and the reporting of PTC&#8217;s first quarter financials to ensure a smooth transition.  </font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;We are grateful for Shane&#8217;s contributions since he joined as our CFO in 2013,&#8221; said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. &#8220;We thank Shane for his service and dedication, as he leaves PTC well-positioned for continued commercial growth.  Our experienced leadership team remains firmly on track to meet our goals and to deliver innovative therapies for DMD and other rare diseases. I am confident in our ability to oversee an efficient and effective transition while we look to appoint a new CFO as promptly as possible.  We wish Shane the very best in his new role.&#8221;</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;It has been a privilege to be part of PTC&#8217;s exciting growth story,&#8221; said Shane Kovacs, Chief Financial Officer, PTC Therapeutics, Inc., &#8220;I am confident that PTC will continue its focus on delivering value for patients and shareholders alike as it pursues its mission of meeting unmet needs of those living with rare diseases.&#8221;</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">About PTC Therapeutics </font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">PTC is a global biopharmaceutical company focused on the discovery, development, and commercialization of novel medicines using our expertise in RNA biology. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders and oncology. PTC has discovered all of its compounds currently under development using its proprietary technologies. Since its founding nearly 20 years ago, PTC' mission has focused on developing treatments to fundamentally change the lives of patients living with rare genetic disorders. The company was founded in 1998 and is headquartered in South Plainfield, New Jersey. For more information on the company, please visit our website www.ptcbio.com.</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">For More Information:</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Investors:</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Emily Hill</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">+ 1 (908) 912-9327</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0000ff;text-decoration:underline;">ehill@ptcbio.com</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Media:</font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Jane Baj</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">+1 (908) 912-9167</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0000ff;text-decoration:underline;">jbaj@ptcbio.com</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Forward Looking Statements:</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This press release contains forward-looking statements addressing PTC&#8217;s pending acquisition of all rights to Emflaza&#8482; (deflazacort) from Marathon Pharmaceuticals, LLC (the &#8220;Transaction&#8221;) and other statements about future expectations that are dependent upon future events or developments. All statements, other than those of historical fact, contained in this press release are forward-looking statements, including statements related to PTC&#8217;s expectations with respect to the closing of the Transaction, the effective date of Mr. Kovacs&#8217; departure, the identification of a successor to Mr. Kovacs, the future expectations, plans and prospects for PTC and PTC's strategy, future operations, future financial position, future revenues or projected costs, and the objectives of management. Other forward-looking statements may be identified by the words "look forward", "plan," "anticipate," "believe," "estimate," "expect," "intend," "may," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions. </font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">PTC&#8217;s actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to satisfaction of the conditions to closing the Transaction in the anticipated timeframe or at all (including the failure to obtain necessary regulatory approvals); PTC&#8217;s ability to realize the anticipated benefits of the Transaction, including the possibility that the expected benefits from the Transaction will not be realized or will not be realized within the expected time period; negative effects of announcements related to the Transaction on the market price of PTC&#8217;s common stock; significant transaction costs, unknown liabilities, and the risk of litigation and/or regulatory actions related to the Transaction as well as other business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of Translarna</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></font><font style="font-family:inherit;font-size:11pt;">&#32;(ataluren) and Emflaza; PTC's ability to resolve the matters set forth in the Refuse to File letter it received from the FDA in connection with its new drug application (NDA) for Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD), including whether PTC's filing of the NDA over protest with the FDA will result in a timely or successful review of the NDA, and whether PTC will be required to perform additional clinical and non-clinical trials or analyses at significant cost, which, if successful, could potentially support the approval of the NDA filed over protest or a new NDA submission; PTC's ability to maintain its marketing authorization of Translarna for the treatment of nmDMD in the European Economic Area (EEA), including whether the European Medicines Agency (EMA) determines in future annual renewal cycles that the benefit-risk balance of Translarna authorization supports renewal of such authorization; PTC's ability to enroll, fund, complete and timely submit to the EMA the results of Study 041, which is a specific obligation to continued marketing authorization in the EEA; the outcome of pricing and reimbursement negotiations in those territories in which PTC may be authorized to sell Translarna for the treatment of nmDMD; PTC's scientific approach and general development progress; the sufficiency of PTC's cash resources and its ability to obtain adequate financing in the future for its foreseeable and unforeseeable operating expenses and capital expenditures; and the factors discussed in the "Risk Factors" section of PTC&#8217;s most recent Annual Report on Form 10-K as well as any updates to these risk factors filed from time to time in PTC's other filings with the SEC. </font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The forward-looking statements contained herein represent PTC's views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual </font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law. </font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>workivalogo.jpg
<TEXT>
begin 644 workivalogo.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M!>('+/.)<O2,4_6U_P FC^I_"C!S?#\)RVE*37I>WYIGZA_L:^)/^$H_9O\
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MMPN!;PW,D<$KAE4JTL*QR%0"%+E0S8W'T*BBOIWOH?EX4444@"BBB@ HHHH
F**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
